Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Entolimod, an Adjuvant for Vaccine Augmentation
NCT03063736Phase 1Completed
- Sponsor
- Baylor College of Medicine
- Start
- Dec 2017
- Primary completion
- Mar 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of entolimod in Tetanus and diphtheria (2 arms), sponsored by Baylor College of Medicine. Primary endpoint: Adverse events associated with entolimod augmentation at 6 weeks. Started Dec 2017; status: completed.
02
Drugs
entolimod
03
Conditions
Tetanusdiphtheria
Beyond the preview
Go deeper on NCT03063736.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03063736.